CN116063289A

CN116063289A - Crystal form, preparation method and application thereof

Info

Publication number: CN116063289A
Application number: CN202111291371.6A
Authority: CN
Inventors: 王文贵; 胡永韩; 汪绪凡; 翁秋萍
Original assignee: Suzhou Sinoway Pharmaceutical Technology Co ltd
Current assignee: Suzhou Sinoway Pharmaceutical Technology Co ltd
Priority date: 2021-11-02
Filing date: 2021-11-02
Publication date: 2023-05-05

Abstract

The invention discloses a crystal form of a multi-substituted benzene ring compound maleate, a preparation method and application thereof.

Description

Crystal form, preparation method and application thereof

Technical Field

The invention relates to a crystal form of a polysubstituted benzene ring compound maleate, a preparation method and application thereof.

Background

A polysubstituted benzene ring compound has a structure as shown in formula I

This compound has been disclosed in patent WO2020020374A1 as an inhibitor of EZH2 (Zeste homolog enhancer 2,Enhancer Of Zeste Homolog 2) and can be used to prevent or treat EZH2 mediated diseases including brain cancer, thyroid cancer, cardiac sarcoma, lung cancer, oral cancer, gastric cancer and various other cancers.

A phenomenon in which a substance exists in two or more different crystal structures is called polymorphism. For drugs, this polymorphism may affect absorption of the drug, and thus affect bioavailability of the drug, thereby exhibiting different clinical effects and toxic and side effects. In view of this, it is of great importance to develop a dominant crystalline form of a salt of a polysubstituted benzene ring compound as shown in formula I with advantageous properties.

In the process of drug development, solubility and hygroscopicity are factors to be considered in drug development, but the solubility and hygroscopicity are usually related to each other to a certain extent, and active raw materials which are easy to dissolve in water can absorb water, so that substances with high solubility are usually easy to absorb moisture. Therefore, the development of compounds with higher solubility and lower hygroscopicity is of great importance for drug development.

Disclosure of Invention

The invention aims to overcome the defects of low solubility and easy moisture absorption of a polysubstituted benzene ring compound shown in a formula I in the prior art in the process of preparing medicines, thereby providing a crystal form of a polysubstituted benzene ring compound salt shown in a formula II, a preparation method and application thereof.

The invention provides a crystal form C of a multi-substituted benzene ring compound maleate shown in a formula II,

the X-ray powder diffraction pattern of the crystal form C of the multi-substituted benzene ring compound maleate shown in the formula II expressed in terms of 2 theta angle can be also basically shown in figure 1.

In the invention, all X-ray powder diffraction patterns are measured by using K alpha spectrum lines of a Cu target.

The invention also provides a pharmaceutical composition, which comprises the crystal form C of the multi-substituted benzene ring compound maleate shown in the formula II and a pharmaceutically acceptable carrier.

The crystal form C of the multi-substituted benzene ring compound maleate shown in the formula II or the pharmaceutical composition can be used for treating and/or preventing EZH2 mediated diseases. Preferably, the EZH 2-mediated disease comprises: cancer, pulmonary hypertension, myelofibrosis, human Immunodeficiency Virus (HIV) disease, graft Versus Host Disease (GVHD), weaver syndrome, psoriasis, liver fibrosis. More preferably, the EZH 2-mediated disease is cancer.

Preferably, the cancer comprises a metastatic or malignant tumor.

Preferably, the cancer includes brain cancer, thyroid cancer, cardiac sarcoma, lung cancer, oral cancer, stomach cancer, liver cancer, kidney cancer, pancreatic cancer, esophageal cancer, nasopharyngeal cancer, laryngeal cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, ovarian cancer, uterine cancer, bone cancer, melanoma, glioblastoma, lymphoma, blood cancer, adrenal neuroblastoma, skin cancer, astrocytoma, and the like.

In the invention, the crystal form C of the multi-substituted benzene ring compound maleate shown in the formula II can also be combined with one or more other active ingredients; when used in combination, the active ingredients may be separate compositions for simultaneous administration by the same or different routes of administration in the treatment or at different times, respectively, or they may be administered together in the same pharmaceutical composition.

In the present invention, the administration method of the pharmaceutical composition is not particularly limited, and various dosage forms of preparation administration can be selected according to the age, sex and other conditions and symptoms of the patient; for example, tablets, pills, solutions, suspensions, emulsions, granules or capsules for oral administration; the injection can be administered alone or mixed with injectable delivery solution (such as glucose solution and amino acid solution) for intravenous injection; suppositories are administered into the rectum.

In some examples, form C of the maleate salt of the polysubstituted benzene ring compound of formula II does not undergo conversion when formulated with one or more pharmaceutically acceptable carriers and/or excipients and/or diluents.

In the present invention, room temperature means 10-35 ℃.

In the present invention, the water activity a of the solvent used _w <0.2。

In the present invention, "control" means "prevention". "preventing" refers to a reduced risk of acquiring or developing a disease or disorder (i.e., resulting in at least one of the clinical symptoms of a disease not occurring in a subject that may be exposed to a disease agent or a disease susceptible prior to onset of the disease).

In the present invention, "treating" refers to ameliorating a disease or disorder (i.e., preventing a disease or reducing its manifestation, the extent or severity of its clinical symptoms); alternatively, at least one physical parameter is improved, which may not be perceived by the subject; or slowing disease progression.

The crystalline forms of the invention may be identified by one or more solid state analysis methods. Such as X-ray powder diffraction, single crystal X-ray diffraction, infrared absorbance spectra, differential scanning calorimeter, thermogravimetric curves, and the like. Those skilled in the art will appreciate that the peak intensity and/or peak condition of X-ray powder diffraction may vary depending on the experimental conditions. Meanwhile, due to different accuracies of the instrument, the measured 2 theta value has an error of about + -0.2 degrees. The relative intensity value of the peak is more dependent on certain properties of the sample to be measured, such as the size of the crystal and the purity, than the position of the peak, so that the measured peak intensity may deviate by about + -20%. Those skilled in the art can obtain sufficient information to identify individual crystalline forms from the X-ray powder diffraction data provided by this patent despite experimental error, instrumental error, orientation priority, and the like. In infrared spectrometry, the shape of the spectrum and the position of the absorption peak are affected to some extent due to different instrument performances of various types, different grinding degrees during preparation of the test sample, different water absorption degrees and the like. In contrast, in DSC measurement, the initial temperature, the maximum temperature and the heat of fusion data of the endothermic peak obtained by actual measurement have a degree of variability depending on the heating rate, the crystal shape and purity and other measurement parameters.

The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.

The reagents and materials used in the present invention are commercially available.

Drawings

FIG. 1 is an X-ray powder diffraction pattern of form C of a maleate salt of a multi-substituted benzene ring compound shown in formula II.

Detailed Description

The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.

The instruments used in the following examples are shown in table 2:

TABLE 2

Powder X-ray diffraction analysis (XRPD):

XRPD patterns were collected on an Empyrean and pamalytical X' Pert3 ray powder diffraction analyzer, scan parameters as in table 3:

TABLE 3 Table 3

Thermogravimetric analysis (TGA) and Differential Scanning Calorimeter (DSC):

TGA and DSC profiles were collected on Discovery 5500 thermogravimetric analyzer and Discovery 2500 differential scanning calorimeter, respectively, parameters as in table 4:

TABLE 4 Table 4

Parameters (parameters)	TGA	DSC
			Method	Linear temperature rise	Linear temperature rise
Sample tray	Aluminum tray open	Aluminum plate and gland
			Temperature range	Room temperature-350 DEG C	25℃-300℃
Scan rate (. Degree. C./min)	10	50
			Protective gas	Nitrogen gas	Nitrogen gas

Dynamic moisture adsorption (DVS)

Dynamic moisture sorption (DVS) curves were collected on DVS intricic of SMS (Surface Measurement Systems). LiCl, mg (NO) ₃ ) ₂ And deliquescence point correction of KCl. DVS test parameters are listed in table 5:

TABLE 5

/>

Liquid nuclear magnetism of hydrogen spectrum ¹ H Solution NMR)

Collecting hydrogen spectrum liquid nuclear magnetic spectrum on Bruker 400M nuclear magnetic resonance apparatus, DMSO-d ₆ As a solvent.

Ultra Performance Liquid Chromatography (UPLC)

The purity and solubility of the samples in the test were measured by waters ultra high performance liquid chromatography under the conditions shown in table 6:

TABLE 6

Example 1: about 20mg of the form B of the maleate salt of the polysubstituted benzene ring compound represented by formula II obtained in example 4 was weighed into a 3-mL vial, about 4mL of saturated salt solution (40-90% RH) was additionally added into a 20-mL vial, and after opening the 3-mL vial into the 20-mL vial, the 20-mL vial was sealed. XRPD testing was performed after 30 days of standing at room temperature. The results are shown in Table 15:

TABLE 15

/>

Comparing the X-ray powder diffraction patterns of the samples obtained in the numbers 1-2 with the patterns of the samples obtained in the numbers 5 of the comparative example 3, and determining that the patterns are all the crystal form B of the multi-substituted benzene ring compound maleate shown in the formula II; the X-ray powder diffraction patterns of the samples obtained by the numbers 3-4 are compared with the pattern of the sample of the comparative example 1 to determine the crystal form C of the multi-substituted benzene ring compound maleate shown in the formula II.

Claims

1. Form C of the maleate salt of a polysubstituted benzene ring compound of formula II, characterized by an X-ray powder diffraction pattern expressed in terms of 2Θ angles substantially as shown in figure 1;

2. a pharmaceutical composition comprising the crystalline form C of the maleate salt of the multi-substituted benzene ring compound of formula II of claim 1, and a pharmaceutically acceptable carrier.

3. Use of a crystalline form C of a maleate salt of a polysubstituted benzene ring compound of formula II as claimed in any of claims 1 or a pharmaceutical composition as claimed in claim 2 for the manufacture of a medicament for the prevention or treatment of EZH2 mediated diseases.

4. The use of claim 3, wherein the EZH2 mediated disease comprises cancer.

5. The use of claim 4, wherein the cancer comprises brain cancer, thyroid cancer, cardiac sarcoma, lung cancer, oral cancer, stomach cancer, liver cancer, kidney cancer, pancreatic cancer, esophageal cancer, nasopharyngeal cancer, laryngeal cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, ovarian cancer, uterine cancer, bone cancer, melanoma, glioblastoma, lymphoma, blood cancer, adrenal neuroblastoma, skin cancer, astrocytoma.